About the Event
Today, a diagnosis of metastatic breast cancer is essentially a death sentence. While CDK Inhibitors can prolong life, 40% of patients don’t respond to current treatments and 100% will become resistant after a short period of time. Thanks to Concarlo, that could change very soon.
Concarlo is a women-lead biotech oncology company focused on diagnosing and treating metastatic breast cancer by targeting a unique cellular pathway. Their lead drug, IpY essentially serves as an off switch for CDK4/6 and CDK2 complexes, blocking tumor growth and preventing remission.
Their approach has been validated by several publications, an NIH SBIR Phase I award, and a contract with the NIH Nanoparticle Characterization Laboratory. In small animal testing, IpY demonstrated greatly increased survivability with tumor regression and no toxicity.
Join our webinar to hear from Concarlo’s CEO and CSO, Dr. Stacy Blain, and COO, LisaMarie Casey, as they discuss the science behind this remarkable breakthrough in the treatment of metastatic breast cancer.